Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
Tomoya FukuiJiichiro SasakiSatoshi IgawaAkiko KadaToshiki I SaitoYoshihito KogureHiroaki OkamotoKatsuhiko NaokiPublished in: BMC cancer (2022)
Japan Registry of Clinical Trials: jRCTs041200100 (registration date: February 12, 2021).